Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 14/20 | 0.67 |
| ▸ | PNP | P00491 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL3861471 | 0.96 | HPRT1 (0.62) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL3861507 | 0.94 | HPRT1 (0.59) | HPRT1PNP | |
| SCHEMBL13714879 | 0.89 | POLB (0.61) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL3861491 | 0.89 | HPRT1 (0.53) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL3861483 | 0.88 | HPRT1 (0.56) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL3861499 | 0.86 | HPRT1 (0.61) | HPRT1PNP | |
| SCHEMBL3853182 | 0.83 | HPRT1 (0.44) | HPRT1PNPCYP3A4 | |
| SCHEMBL13714781 | 0.83 | HPRT1 (0.44) | HPRT1PNPCYP3A4 | |
| SCHEMBL13714779 | 0.82 | HPRT1 (0.43) | HPRT1PNP | |
| SCHEMBL6901448 | 0.80 | HPRT1 (0.76) | HPRT1PNPBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | HPRT1 16/4885PNP 15/4885MEN1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.